Skip to main content

by Dr. C.H. Weaver M.D. 6/2021 ASCO update

The tyrosine kinase inhibitor Anlotinib (catequentinib) delayed time to cancer progression and prolonged survival among patients with soft tissue sarcoma who regressed on or were intolerant to anthracycline-based chemotherapy, according to data presented at the 2021 Annual American Society of Clinical Oncology Meeting.

Chinese doctors assessed 233 Chinese patients with undifferentiated pleomorphic sarcoma, liposarcoma, leiomyosarcoma, synovial sarcoma, alveolar soft part sarcoma, fibrosarcoma, clear cell sarcoma or epithelioid sarcoma who were treated with anlotinib or a placebo and directly compared.

Sarcoma Bone CancerConnect 490

The overall response rate for anlotinib was 10% and the median time to cancer progression was 6.27 months compared with 1.47 months for placebo treated patients.

The overall response to treatment was 10% among those treated with anlotinib compared with 1.3% for placebo. The disease control rate also was higher with anlotinib.

In a subgroup analysis, patients with synovial sarcoma leiomyosarcoma, and alveolar soft part sarcoma all had significant improvements, however, among patients with undifferentiated pleomorphic sarcoma, liposarcoma, fibrosarcoma, and clear cell sarcoma the improvements seen with anlotinib were not significant.

Scroll to Continue

Recommended Articles

Sarcoma Bone Newsletter 490

Catequentinib improved disease control and progression-free survival in patients with advanced synovial sarcoma compared with dacarbazine.

Catequentinib (Anlotinib) improved disease control and progression-free survival (PFS) in patients with advanced previously treated synovial sarcoma compared with dacarbazine, according to updated data from the phase 3 APROMISS study presented during the 2021 ASCO Annual Meeting.2 Approximately 30% of Anlotinib treated patients survived cancer free one year from treatment compared to only 4% of those treated with dacarbazine.2,3

Ongoing comparative trials are currently enrolling patients in the United States.


  1. Chi Y, et al. Abstract 11503. Presented at ASCO Annual Meeting; June 1-5, 2018; Chicago.
  2. Van Tine BA, Chawla SP, Trent JC, et al. A phase III study (APROMISS) of AL3818 (Catequentinib, Anlotinib) hydrochloride monotherapy in subjects with metastatic or advanced synovial sarcoma. J Clin Oncol. 2021;39(suppl 15):11505. doi:10.1200/JCO.2021.39.15_suppl.11505
  3. Gao Y, Liu P, Shi R. Anlotinib as a molecular targeted therapy for tumors. Oncol Lett. 2020;20(2):1001-1014. doi:10.3892/ol.2020.11685